Prospective evaluation of 18F-DCFPyL PET/CT in detection of high-risk localized prostate cancer: Comparison with mpMRI

Sonia Gaur, Esther Mena, Stephanie A. Harmon, Maria L. Lindenberg, Stephen Adler, Anita T. Ton, Joanna H. Shih, Sherif Mehralivand, Maria J. Merino, Bradford J. Wood, Peter A. Pinto, Ronnie C. Mease, Martin G. Pomper, Peter L. Choyke, Baris Turkbey

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


OBJECTIVE. The purpose of this study was to assess the utility of PET with (2S)-2-[[(1S)-1-carboxy-5-[(6-(18F)fluoranylpyridine-3-carbonyl)amino]pentyl]carbamoylamino]pentanedioic acid (18F-DCFPyL), a prostate-specific membrane antigen (PSMA)-targeted radiotracer, in the detection of high-risk localized prostate cancer as compared with multiparametric MRI (mpMRI). SUBJECTS AND METHODS. This HIPAA-compliant prospective study included 26 consecutive patients with localized high-risk prostate cancer (median age, 69.5 years [range, 53–81 years]; median prostate-specific antigen [PSA] level, 18.88 ng/mL [range, 1.03–20.00 ng/mL]) imaged with 18F-DCFPyL PET/CT and mpMRI. Images from PET/CT and mpMRI were evaluated separately, and suspicious areas underwent targeted biopsy. Lesion-based sensitivity and tumor detection rate were compared for PSMA PET and mpMRI. Standardized uptake value (SUV) and PSMA PET parameters were correlated with histopathology score, and uptake in tumor was compared with that in nonmalignant tissue. On a patient level, SUV and PSMA tumor volume were correlated with PSA density. RESULTS. Forty-four tumors (one in Gleason grade [GG] group 1, 12 in GG group 2, seven in GG group 3, nine in GG group 4, and 15 in GG group 5) were identified at histopathology. Sensitivity and tumor detection rate of 18F-DCFPyL PET/CT and mpMRI were similar (PET/CT, 90.9% and 80%; mpMRI, 86.4% and 88.4%; p = 0.58/0.17). Total lesion PSMA and PSMA tumor volume showed a relationship with GG (τ = 0.27 and p = 0.08, τ = 0.30 and p = 0.06, respectively). Maximum SUV in tumor was significantly higher than that in nonmalignant tissue (p < 0.05). Tumor burden density moderately correlated with PSA density (r = 0.47, p = 0.01). Five true-positive tumors identified on 18F-DCFPyL PET/CT were not identified on mpMRI. CONCLUSION. In patients with high-risk prostate cancer, 18F-DCFPyL PET/CT is highly sensitive in detecting intraprostatic tumors and can detect tumors missed on mpMRI. Measured uptake is significantly higher in tumor tissue, and PSMA-derived tumor burden is associated with severity of disease.

Original languageEnglish (US)
Pages (from-to)652-659
Number of pages8
JournalAmerican Journal of Roentgenology
Issue number3
StatePublished - Sep 2020


  • MRI
  • Multiparametric MRI
  • PET
  • Prostate
  • Prostate cancer
  • Prostate-specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Prospective evaluation of 18F-DCFPyL PET/CT in detection of high-risk localized prostate cancer: Comparison with mpMRI'. Together they form a unique fingerprint.

Cite this